Experience with Intravitreal Bevacizumab as a Preoperative Adjunct in 23-G Vitrectomy for Advanced Proliferative Diabetic Retinopathy
- 1 November 2010
- journal article
- research article
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 20 (6), 1047-1052
- https://doi.org/10.1177/112067211002000604
Abstract
Purpose To evaluate the safety and efficacy of intravitreal injection of bevacizumab before vitrectomy in advanced proliferative diabetic retinopathy. Methods A randomized clinical trial was performed on 40 eyes of 40 patients. Inclusion criteria were advanced proliferative diabetic retinopathy with fractional retinal detachment and HbA1c <7%. Patients were randomly assigned into 2 groups. Patients in one group had an intravitreal injection (1.25 mg) of bevacizumab 48 hours before 23-G pars plana vitrectomy surgery was performed, whereas the other group did not. Best-corrected visual acuity, intraocular pressure, and fundus photographs were taken prior to surgery 1 week and 3 and 6 months postoperatively. Results Effective vitrectomy time was 8.05 minutes in the bevacizumab group vs 16.8 minutes in the non-bevacizumab group. Statistically significant differences were observed in visual acuity at 1 week and 3 and 6 months follow-up between the 2 groups (p<0.05 for each visit). Also, there was less bleeding intraoperatively in the bevacizumab group. Mean final visual acuity in the bevacizumab group was 0.82 logMAR and 2.01 logMAR in the non-bevacizumab group. Conclusions Adjuvant intravitreal injection of bevacizumab prior to vitrectomy in diabetic retinopathy with fractional retinal detachment significantly eases the procedure, diminishing intraoperative complications, and leads to a better visual outcome.Keywords
This publication has 28 references indexed in Scilit:
- Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathyEye, 2007
- Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-upEye, 2007
- USE OF INTRAVITREAL BEVACIZUMAB AS A PREOPERATIVE ADJUNCT FOR TRACTIONAL RETINAL DETACHMENT REPAIR IN SEVERE PROLIFERATIVE DIABETIC RETINOPATHYRetina, 2006
- Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapyBiochemical and Biophysical Research Communications, 2005
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005
- Pegaptanib for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2004
- Long-term results of vitreous surgery for proliferative diabetic retinopathyDocumenta Ophthalmologica, 1994
- Macular detachment following laser treatment for proliferative diabetic retinopathyAlbrecht von Graefes Archiv für Ophthalmologie, 1990
- Two-year Course of Visual Acuity in Severe Proliferative Diabetic Retinopathy with Conventional ManagementOphthalmology, 1985